Gadolinium deposition in nephrogenic fibrosing dermopathy

Boyd, Alan S.; Zic, John A.; Abraham, Jerrold L.

doi:10.1016/j.jaad.2006.10.048

Cited by 345 publications

(250 citation statements)

References 9 publications

Supporting

Mentioning

238

Contrasting

Unclassified

Order By: Relevance

“…Potential applications of PACE DWI include patients who are not able to hold their breath sufficiently and patients in whom better image quality (higher SNR and/or spatial resolution) is needed. These include for example patients with severe renal dysfunction who cannot receive Gadolinium chelates, at risk of nephrogenic systemic fibrosis (21)(22)(23)(24) and for assessment of tumor treatment response (6,11,14). In our study, we did not modify the spatial resolution, but we did use a higher number of averages with the PACE DWI sequence, thus the improved SNR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diffusion‐weighted imaging of the liver: Comparison of navigator triggered and breathhold acquisitions

Taouli

Sandberg

Stemmer

et al. 2009

Magnetic Resonance Imaging

150

122

View full text Add to dashboard Cite

Purpose: To compare a free breathing navigator triggered single shot echoplanar imaging (SS EPI) diffusion-weighted imaging (DWI) sequence with prospective acquisition correction (PACE) with a breathhold (BH) DWI sequence for liver imaging. Materials and Methods:Thirty-four patients were evaluated with PACE-DWI and BH DWI of the liver using bvalues of 0, 50, and 500 s/mm 2 . There were 29 focal liver lesions in 18 patients. Qualitative evaluation was performed on a 3-point scale (1-3) by two independent observers (maximum score 9). Quantitative evaluation included estimated SNR (signal to noise ratio), lesion-to-liver contrast ratio, liver and lesion apparent diffusion coefficients (ADCs), and coefficient of variation (CV) of ADC in liver parenchyma and focal liver lesions (estimate of noise contamination in ADC).Results: PACE-DWI showed significantly better image quality, higher SNR and lesion-to-liver contrast ratio when compared with BH DWI. ADCs of liver and focal lesions with both sequences were significantly correlated (r ϭ 0.838 for liver parenchyma, and 0.904 for lesions, P Ͻ 0.0001), but lower with the BH sequence (P Ͻ 0.02). There was higher noise contamination in ADC measurement obtained with BH DWI (with a significantly higher SD and CV of ADC). Conclusion:The use of a navigator echo to trigger SS EPI DWI improves image quality and liver to lesion contrast, and enables a more precise ADC quantification compared with BH DWI acquisition. THERE IS A GROWING interest in using liver diffusionweighted imaging (DWI) for lesion detection and characterization, prediction of treatment response and assessment of chronic liver disease, by means of apparent diffusion coefficient (ADC) measurement (1-20). The interest in DWI is motivated by the recently described risk of nephrogenic systemic fibrosis (21-24), which makes DWI an attractive alternate method to Gadolinium-enhanced sequences. Most prior studies have used breathhold (BH) single shot echoplanar imaging (SS EPI) to acquire diffusion-weighted images, using various sets of b-values. SS EPI sequences are very fast, however, suffer from limited image quality, mostly related to limited signal to noise ratio (SNR) especially at higher b-values, and limited spatial resolution, which constitute an obstacle for its widespread use in clinical practice. Techniques such as parallel imaging (25,26) and pulse triggering (27) have been proposed to improve SS EPI image quality and precision of ADC measurement.There are several recent reports on the use of respiratory triggered acquisitions for liver DWI (15,16,[28][29][30][31]. However, only two studies have specifically compared different diffusion acquisition schemes for liver imaging (28,30). The first study (28) included a population of patients with liver lesions, and compared image quality and ADC of free breathing versus BH DWI. The second study included healthy volunteers, and compared BH, free breathing and respiratory triggered DWI (without navigator echoes) (30). There are, however, no reports on the use of a...

show abstract

Section: Discussionmentioning

confidence: 99%

“…The interest in DWI is motivated by the recently described risk of nephrogenic systemic fibrosis (21)(22)(23)(24), which makes DWI an attractive alternate method to Gadolinium-enhanced sequences. Most prior studies have used breathhold (BH) single shot echoplanar imaging (SS EPI) to acquire diffusion-weighted images, using various sets of b-values.…”

mentioning

confidence: 99%

Diffusion‐weighted imaging of the liver: Comparison of navigator triggered and breathhold acquisitions

Taouli

Sandberg

Stemmer

et al. 2009

Magnetic Resonance Imaging

150

122

View full text Add to dashboard Cite

show abstract

“…Onset is within a few days to a few months of administration. Gadolinium has now been found in the skin in biopsies from some patients (22,23). This finding has strengthened the hypothesis that "free" 1 gadolinium liberated from the complex by a process of transmetallation, a process in which gadolinium is replaced in the chelate by other ions, plays a direct role in the pathogenesis of the disease.…”

mentioning

confidence: 70%

“…In addition to the phenomenon of CIN with the Gd chelates, we have seen the emergence of a new condition, nephrogenic systemic fibrosis (NSF), which is associated with, if as yet not definitively proven to be caused by, Gd chelate administration to patients with end-stage renal failure (ESRF) and perhaps other serious medical conditions (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

mentioning

confidence: 99%

Nephrogenic systemic fibrosis: Possible mechanisms and imaging management strategies

Dawson

2008

Magnetic Resonance Imaging

View full text Add to dashboard Cite

“…In the published literature the onset of NSF after Gd-CA varies between a few days to several months (13,14,16,50,58,59). However, the exact time between Gd-CA exposure and the first sign of symptoms is difficult to ascertain because it depends on the patients' awareness and reporting.…”

Section: Onset Of Diseasementioning

confidence: 99%

Nephrogenic systemic fibrosis: Clinical spectrum of disease

Mayr

Burkhalter

Bongartz

2009

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Nephrogenic systemic fibrosis (NSF) is a rare systemic fibrosing disorder that primarily affects the skin and the subcutaneous structures. Also, there are reports of involvement of deeper structures and organs in the human body, but the confirmation of systemic involvement is complicated by overlap of other disease processes that occur in patients with severe renal impairment. The disorder leads to significant disability and is an important contributing factor of death. Virtually all patients who developed NSF suffered from endstage renal disease (ESRD) or severe chronic kidney disease (CKD) or from an acute acquired kidney injury (AKI). There is an increase in evidence that a causal relation between gadolinium‐based contrast agents (Gd‐CA) and NSF is probable. Therefore, advanced kidney injury and the exposure to Gd‐CA are regarded as prerequisites to develop NSF. Overall, the prognosis is poor and there is no established therapy that shows a consistent benefit. The purpose of this review is to discuss the clinical spectrum of the disease. The clinical presentation, role of co‐morbidity in disease development and manifestation, time course, prognosis, outcome, and epidemiological aspects are especially reviewed. J. Magn. Reson. Imaging 2009;30:1289–1297. © 2009 Wiley‐Liss, Inc.

show abstract

Gadolinium deposition in nephrogenic fibrosing dermopathy

Cited by 345 publications

References 9 publications

Diffusion‐weighted imaging of the liver: Comparison of navigator triggered and breathhold acquisitions

Diffusion‐weighted imaging of the liver: Comparison of navigator triggered and breathhold acquisitions

Nephrogenic systemic fibrosis: Possible mechanisms and imaging management strategies

Nephrogenic systemic fibrosis: Clinical spectrum of disease

Contact Info

Product

Resources

About